Entrada Therapeutics (TRDA) Retained Earnings (2020 - 2026)

Entrada Therapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at $246000.0 for Q1 2026.

• In Q1 2026, Retained Earnings fell 43.71% year-over-year to $246000.0; the TTM figure through Mar 2026 stood at $246000.0 (down 43.71% YoY), while the FY2025 annual figure was -$273.1 million, down 111.14% from the prior year.
• Retained Earnings was $246000.0 for Q1 2026 at Entrada Therapeutics, up from -$273.1 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $972000.0 in Q3 2024 to a low of -$273.1 million in Q4 2025.
• Historically, Retained Earnings has averaged -$125.2 million across 5 years, with a median of -$138.5 million in 2022.
• Biggest YoY gain for Retained Earnings was 100.52% in 2024; the steepest drop was 66430.26% in 2024.
• A 5-year view of Retained Earnings shows it stood at -$188.3 million in 2022, then surged by 100.1% to $195000.0 in 2023, then tumbled by 66430.26% to -$129.3 million in 2024, then plunged by 111.14% to -$273.1 million in 2025, then surged by 100.09% to $246000.0 in 2026.
• The last three Retained Earnings figures came in at $246000.0 (Q1 2026), -$273.1 million (Q4 2025), and -$233.9 million (Q3 2025), per Business Quant data.